首页> 外文期刊>Scandinavian journal of urology and nephrology >Long-term Effects of Losartan on Proteinuria and Renal Function in Patients with Renal Amyloidosis.
【24h】

Long-term Effects of Losartan on Proteinuria and Renal Function in Patients with Renal Amyloidosis.

机译:氯沙坦对肾淀粉样变性患者蛋白尿和肾功能的长期影响。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Objective: To investigate the effect of the angiotensin II receptor antagonist losartan on proteinuria in secondary amyloidosis cases. Material and Methods: Sixteen patients with renal biopsy-proven AA amyloidosis with proteinuria were included in the study. All the patients had received colchicine treatment for at least 18 months. The patients were divided into two groups with similar age and gender distributions. Eight patients were given losartan at a dose of 50 mg/day for 12 months and the other 8 patients served as controls. Mean arterial blood pressure, proteinuria, serum albumin level and renal function were determined at the initiation of the study and after 1 and 12 months. Results: There were no significant differences in proteinuria, serum albumin level, renal function or mean arterial blood pressure at the initiation of the study. In the losartan group daily proteinuria decreased significantly from 5.2 +/- 0.7 g at the initiation of the study to 3.9 +/- 1.2 g at 1 month and 3.6 +/- 0.8 g at12 months, while in the control group it changed from 4.6 +/- 1.0 g to 4.7 +/- 1.0 g and 6.1 +/- 1.2 g, respectively. The increment at 12 months was significant. After 12 months of treatment with losartan, proteinuria was significantly lower in comparison to the degree of proteinuria in the control group. Serum albumin level increased significantly in the losartan group but was unchanged in the control group. In the control group, creatinine clearance showed a significant decrease. There was no significant difference in mean arterial blood pressure measurements, serum creatinine levels, total protein, albumin and creatinine clearance levels between the two groups. Conclusions: Losartan seemed to prevent an increase in proteinuria without altering the creatinine clearance level in patients with amyloidosis type AA during a 12-month period. This indicates that losartan may be used to decrease proteinuria in this patient group. However, our results are only preliminary and need to be confirmed by larger studies.
机译:目的:探讨血管紧张素Ⅱ受体拮抗剂氯沙坦对继发性淀粉样变性病患者蛋白尿的影响。材料与方法:纳入16例经肾活检证实为AA淀粉样变性病伴蛋白尿的患者。所有患者均接受秋水仙碱治疗至少18个月。将患者分为年龄和性别分布相似的两组。 8例患者接受50毫克/天的氯沙坦剂量治疗,持续12个月,其余8例作为对照组。在研究开始时以及术后1和12个月测定平均动脉血压,蛋白尿,血清白蛋白水平和肾功能。结果:在研究开始时,蛋白尿,血清白蛋白水平,肾功能或平均动脉血压无明显差异。在氯沙坦组中,每日蛋白尿从研究开始时的5.2 +/- 0.7 g显着降低至第1个月的3.9 +/- 1.2 g和第12个月的3.6 +/- 0.8 g,而对照组则从4.6改变为分别为+/- 1.0 g至4.7 +/- 1.0 g和6.1 +/- 1.2 g。 12个月时的增加是显着的。氯沙坦治疗12个月后,蛋白尿明显低于对照组的蛋白尿程度。氯沙坦组的血清白蛋白水平显着升高,而对照组则没有变化。在对照组中,肌酐清除率显着降低。两组之间的平均动脉压测量值,血清肌酐水平,总蛋白,白蛋白和肌酐清除率水平无显着差异。结论:在12个月的时间里,氯沙坦似乎可以预防蛋白尿增加,而不会改变A型淀粉样变性病患者的肌酐清除率。这表明氯沙坦可用于降低该患者组的蛋白尿。但是,我们的结果只是初步的,需要进一步的研究证实。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号